JNJ Johnson & Johnson

$JNJ I would love to see the JnJ CEO give updates on acquisitions and talk about what they are doing to make sure they reach valuable assets before competitors do! $SLS

With $JNJ being mentioned again in discussions around a potential $SLS acquisition, it’s worth revisiting some interesting connections. • JNJ has a major hematology/oncology franchise and the global infrastructure to commercialize GPS. • REGAL Phase 3 is approaching its final OS readout. Strong results could significantly increase GPS’s strategic value. • SLS009 represents a second oncology asset with potential applications beyond AML. • SLS director Katherine Bach Kalin previously held senior positions at both JNJ and Celgene. • JNJ Innovative Medicine chairman Tom Cavanaugh also has a significant Celgene background. • SLS director Robert Van Nostrand was associated with Intra-Cellular Therapies, acquired by JNJ for approximately $14.6B. • A JNJ employee has also publicly expressed interest in GPS on LinkedIn. Coincidence? Maybe, maybe not...

$JNJ $MRNA $SLS MRNA Shorts have been squeezed from $25 to $243+ on there Phase 3 cancer vaccine success. $SLS will ascend in the same pattern in the coming hours and days ahead as we approach The next Chapter. ✌️🙏❤️‍🩹

$JNJ $SLS $MRK This is Merck's war to lose, and J&J is the wolf at the door. If Johnson & Johnson captures the $SLS platform, Merck ($MRK) faces absolute oncological extinction.

$JNJ $SLS Part 3. Johnson & Johnson (JNJ) has an estimated near-term “firepower" or buyout capacity of $30 billion to $40 billion without risking its elite AA credit rating. ✌️🙏❤️‍🩹

$JNJ $MRNA $SLS Moderna Rise from the Ashes due to it’s Cancer vaccine success which is partnered with $MRK 50/50 should put fear of God in every short. $SLS owns GPS outright 100% will Put fear of god in the coming days. Shorts will be liquidated here very soon. Shorts are running out of time. ⌛️ ✌️🙏❤️‍🩹

$JNJ $SLS The higher their share price the more currency they have. Whoever acquires SLS will almost immediately start 5-10 new trials for each asset if not more.

$JNJ will be leader in oncology in the future, especially should they (hopefully) acquire $SLS

$JNJ NOV20 265C · still actionable Zone: $252.01 to $255.57 Invalidation: close under $245.17 Objectives: $265.35, then $281.07 The math: up 4.6% to the first objective and 10.7% to the second, against 3.4% risk on the invalidation, better than 3 to 1 to the second Dear friend, picture a big steady company that just took a hard knock and then stood back up. Johnson and Johnson beat its October 13 earnings estimate and the stock fell to $245.17 that day, then buyers stepped in and held the price above that low through a choppy week. That is a swing setup to me, a washed out name holding a real level with room to walk back toward $265.35 first. What that means is simple, we risk a close under the earnings day low to see if the bounce can grow legs. P.S. Watch $251.50, the low from the latest session, because holding above it keeps the bounce picture clean.

$JNJ $AVR J&J has spent roughly $30B building a heart business and still doesn't have a valve. Abiomed: ~$16.6B (2022) Shockwave: ~$13.1B (2024) Laminar: $400M upfront (2023) Atraverse: announced this year And Q3 wasn't pretty. MedTech grew 2.5%, below their own targets. Cardio slowed to 4.3% after running double digits. Abiomed actually shrank 2.3%. Schmid: "we can do better, and we absolutely will." That's heart recovery, circulation, rhythm and LAA covered. No TAVR. They're the only major cardio player sitting out one of the biggest device markets in cardiology. Everyone else is picking a balloon-expandable bet. BSX put $1.5B into MiRus. Medtronic took a stake in Anteris. Abbott is building its own, still at 11 patients in feasibility. Wolk on the call: "We always are on the lookout for strategic drivers that could complement our business." Not many independent BE platforms with real data left, let alone differentiated like duravr! This is masqueraded on purpose imo

$JNJ NOV20 265C · still actionable Zone: $253.77 to $257.35 Invalidation: close under $245.17 Objectives: $264.39, then $281.07 The math: up 3.5% to the first objective and 10.0% to the second, against 4.1% risk on the invalidation, about 2.4 to 1 to the second Think of this swing setup like a sturdy old house that took a loud knock on the door and did not move. Johnson and Johnson reported earnings on October 13 and beat what analysts expected, yet price dipped to $245.17 that day before buyers stepped back in and carried it to a $255.56 close on Friday, up 0.9 percent that day. What that means is simple. The low after the report is now our floor, and above us sits the $264.39 high from before the report and then the $281.07 yearly high. If price closes under $245.17 that floor has given way and you step aside. P.S. Watch $254 on Monday. It was the low on Friday, and a second hold there would show buyers are still defending the recovery.

$JNJ | JOHNSON & JOHNSON Q3 2026 EARNINGS HIGHLIGHTS ◆ EPS: $2.59 vs. $2.52 est. ✅ ◆ Revenue: $25.40B vs. $25.38B est. ✅ ◆ Adjusted Net Earnings: $6.34B (-6.8% YoY) ◆ Net Income: $0.21B (-95.9% YoY) ◆ YTD Free Cash Flow: ~$15.10B (+6.1% YoY) ◆ Innovative Medicine Sales: $16.76B (+7.7% YoY) Segment Performance: ◆ Innovative Medicine: $16.76B (+7.7% YoY) ◆ MedTech: $8.64B (+2.5% YoY) Key Metrics: ◆ GAAP EPS of $0.09 (vs. $2.12 prior year) reflects one-time talc litigation charge, Firefly Bio acquisition, and Sail Biomedicines collaboration. ◆ JNJ announced a proposed resolution of ovarian talc litigation, a significant contingent liability for the company. ◆ FDA approved IMAAVY for wAIHA and authorized OTTAVA robotic surgical system; RYBREVANT FASPRO received Priority Review. Forward Guidance: ◆ FY2026 Estimated Reported Sales: $101.0B-$101.4B (midpoint $101.2B), +7.2%-7.6% YoY; raised from prior midpoint of $101.1B. ◆ FY2026 Adjusted EPS (Diluted): $11.05-$11.15 (midpoint $11.10), +2.4%-3.3% YoY; raised $0.06 from prior midpoint. ◆ FY2026 Adjusted Operational EPS (Diluted): $10.95-$11.05 (midpoint $11.00), +1.5%-2.4% YoY; raised from prior midpoint of $10.94. ◆ FY2026 Adjusted Operational Sales growth: 6.4%-6.8% (midpoint 6.6%); raised from prior midpoint of 6.5%.

$JNJ Trending from 5 posts today? One Ai pic I stole from a Sellas homie, reshared 2 times, eyeballs 👀, and a comment about earnings Tuesday. What kind of scam site is this? 🤣 Oh 40 Billy buyout or bust.

$JNJ will go up at least through the election as a safe haven from election uncertainty. likely rotation from tech sector if democrats take the house due to perceived hostility to data center buildout. republicans retaining power is short term broad-sector bearish due to threats of new iran war, bullish for defense, possible minor bullish for safe haven stocks. democrats taking power is short term bullish if it prevents a new iran war + depending how much democrats gain potential long term bullish if it means increased healthcare spending.

$JNJ Load up on the drop! Happens on earnings with JNJ but shares recover. Very positive comments from Jim Creamer on MAD Money.

$JNJ #ESMO Johnson & Johnson advances the next generation of solid tumor therapies with new data at ESMO 2026. First readout following acquisition of the RIPTAC™ platform shows promising anti-tumor activity with JNJ-6143, a novel oral investigational molecule, in difficult-to-treat prostate cancer. It offers a completely new way of thinking about cancer therapy.

$JNJ "Trade Idea 2: Buy the October 265/267.50 Call Spread ($1.30) and sell the October 252.50 Put for 25 cents." looks to expire, a bust. can buy to close puts after IV falls to release margin

$JNJ This will be a lot higher next week with rotation out of technology stocks and into blue chip, defensive, safe quality with great dividend payout to boot🚀🚀🚀🚀

$JNJ I think what he's trying to say is STFU. This experience will be much more enjoyable after muting you

https://www.cnbc.com/2026/10/09/jim-cramer-week-ahead-bank-earnings-ai-chips.html $JNJ Club holding Johnson & Johnson also reports Tuesday. Cramer said the stock often sells off during its earnings call despite strong underlying results, creating a potential buying opportunity. “With 18 potential blockbuster drugs in the pipeline and among the best cardio and oncology franchises, J&J needs to be bought when it gets crushed,” he said.